SUMMARY Plasma levels of circulating carcinoembryonic antigen (CEA) 
surgery, chemotherapy, and/or radiotherapy in patients with cancer of the gut is widely accepted. Rising levels of circulating CEA are associated with primary or disseminating malignancy of poor prognosis (Reynoso et al, 1972; Zamcheck, Moore, Dhar, and Kupchik, 1972; Moore, Kantrowitz, and Dhar, Moore, Zamcheck, and Kupchik, 1972) .
We therefore began a long-term study of patients with chronic inflammatory disease of the gastrointestinal tract at high risk for cancer of the colon (Fennessy, Sparberg, and Kirsner, 1968; Devroede, Taylor, Sauer, Jackman, and Stickler, 1971 ; Truelove, 1971 The relationship of severity of disease to the presence of circulating CEA is shown in tables J1 and III. Patients who were in remission or had mild symptoms at the time of bleeding had similar CEA positivity in both disease categories. However, CEApositive patients with low disease activity who had ulcerative disease were only barely positive (2-6 ng/ml) whereas those with granulomatous disease sometimes showed high levels of CEA (up to 14.3 ng/ml). Patients with moderate or severe inflammatory disease at the time of testing had Moore et al (1972) , and 35% by Snyder and Miller (1973) . Development of CEA radioimmunoassays had given rise to the hope for earlier detection of cancer for some patients at high risk for colonic cancer, namely those with inflammatory bowel disease (Thompson et al, 1969; LoGerfo et al, 1971) . From our present studies, however, there is no evidence that the CEA level at one point in time correlates with any known risk factors for cancer of the gut.
The present data confirm our earlier finding ) that the incidence of CEA positivity was the same in both ulcerative and granulomatous bowel disease, even though ulcerative colitis is considered to carry the higher cancer risk (Fennessy et al, 1968; Devroede et al, 1971; Truelove, 1971) . We have also found that CEA levels are higher earlier in the disease, whereas the cancer risk increases later.
Moreover, CEA positivity in our present series was inversely related to age while the risk of cancer increases with advancing age.
Finally, circulating CEA levels greater than 5 ng/ml were found in approximately 15% of our population with chronic inflammatory bowel disease and at borderline CEA levels (2-5-4-9 ng/ml) in 23 % of these patients. None of these patients had any clinical indication of colon cancer. While patients with 2-5-5 ng/ml are in a range similar to patients with primary adenocarcinomas of the colon, it is also the range for greatest variability in the interpretation of the significance of CEA radioimmunoassay .
In support of recent findings of Moore et al (1972) those data suggest that a single measurement of CEA cannot be indicative of cancer prognosis in patients with inflammatory bowel disease. On the other hand, sequential CEA assays must be followed for increasing or persisting CEA levels to interpret any initial findings correctly, especially since Moore et al (1972) did not find any case of persisting antigenaemia in inflammatory bowel disease except in the presence of colonic adenocarcinoma. Increasing or persisting levels of CEA unrelated to increasing severity of disease in any given patient would therefore warrant a thorough clinical work up.
Total colectomy significantly reduced the occurrence of positive circulating levels of carcinoembryonic antigen. These data are in accord with the idea that CEA levels reflect the extent of bowel involvement and severity of disease. Such data also suggest that the CEA measured in the circulation of patients with inflammatory bowel disease was of colonic or ileal origin.
We initially proposed the idea that regeneration and/or degeneration of colonic mucosa in diseases involving the ileum or colon might simulate mucosal processes not unlike those found early in embryonic development or in carcinoma of the gut . The uncontrolled expression of many normal antigens has been found in other tumour systems. That certain glycoproteins may be produced which crossreact with CEA during periods of rapid mucosal turnover is not improbable. Certainly these glycoprotein antigens appear in measurable quantities in plasmas of patients with both ulcerative colitis and granulomatous disease.
In conclusion, our findings suggest that a single CEA radioimmunoassay by present methods cannot identify those patients with chronic inflammatory bowel disease who bear the highest risk for cancer. While current CEA radioimmunoassays may be of prognostic value in the postoperative evaluation of patients with cancer of the gut (Reynoso et al, 1972; Moore et al, 1972) , our data suggest that more specific radioimmunoassays for antigens released by inflammatory processes might clarify the significance of the current broad-spectrum CEA radioimmunoassays. Long-term studies utilizing classic clinical criteria, current CEA radioimmunoassays, and more specific radioimmunoassays for CEA-reacting molecules released by regenerating and degenerating colonic mucosa may clarify the relationship of the various circulating forms of CEA-reacting molecules to inflammatory bowel disease and cancer. 
